Literature DB >> 28671339

Role of ErbB/HER family of receptor tyrosine kinases in cholangiocyte biology.

Anna Pellat1, Javier Vaquero1,2, Laura Fouassier1.   

Abstract

The ErbB/HER family comprises four distinct tyrosine kinase receptors, EGFR/ErbB1/HER1, ErbB2/HER2, ErbB3/HER3, and ErbB4/HER4, which trigger intracellular signals at the origin of essential cellular functions, including differentiation, proliferation, survival, and migration. Epithelial cells, named cholangiocytes, that line intrahepatic and extrahepatic bile ducts, contribute substantially to biliary secretory functions and bile transport. Although ErbB receptors have been widely studied in cholangiocarcinoma (CCA), a malignancy of the biliary tract, knowledge of these receptors in biliary epithelium physiology and in non-malignant cholangiopathies is far from complete. Current knowledge suggests a role for epidermal growth factor receptor (EGFR) in cholangiocyte specification and proliferation, and in hepatocyte transdifferentiation into cholangiocytes during liver regeneration to restore biliary epithelium integrity. High expression and activation of EGFR and/or ErbB2 were recently demonstrated in biliary lithiasis and primary sclerosing cholangitis, two cholangiopathies regarded as risk factors for CCA. In CCA, ErbB receptors are frequently overexpressed, leading to tumor progression and low prognosis. Anti-ErbB therapies were efficient only in preclinical trials and have suggested the existence of resistance mechanisms with the need to identify predictive factors of therapy response. This review aims to compile the current knowledge on the functions of ErbB receptors in physiology and physiopathology of the biliary epithelium. (Hepatology 2018;67:762-773).
© 2017 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28671339     DOI: 10.1002/hep.29350

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  20 in total

1.  Suppression of systemic inflammation and signs of acute and chronic cholangitis by multi-kinase inhibitor 1-(4-Cl-benzyl)-3-chloro-4-(CF3-phenylamino)-1H-pyrrole-2,5-dione.

Authors:  Halyna Kuznietsova; Iryna Byelinska; Natalia Dziubenko; Oksana Lynchak; Demyd Milokhov; Olga Khilya; Nataliya Finiuk; Olga Klyuchivska; Rostyslav Stoika; Volodymyr Rybalchenko
Journal:  Mol Cell Biochem       Date:  2021-04-01       Impact factor: 3.396

2.  Incidence, risk and prognostic role of anti-epidermal growth factor receptor-induced skin rash in biliary cancer: a meta-analysis.

Authors:  Fangqiang Wei; Donghun Shin; Xiujun Cai
Journal:  Int J Clin Oncol       Date:  2017-12-30       Impact factor: 3.402

Review 3.  Imaging strategies for receptor tyrosine kinase dimers in living cells.

Authors:  Xia Zhang; Jiaqi Yin; Wei Pan; Yanhua Li; Na Li; Bo Tang
Journal:  Anal Bioanal Chem       Date:  2022-10-03       Impact factor: 4.478

4.  Kinome profiling of cholangiocarcinoma organoids reveals potential druggable targets that hold promise for treatment stratification.

Authors:  Ruby Lieshout; Alessandra V S Faria; Monique M A Verstegen; Gwenny M Fuhler; Maikel P Peppelenbosch; Luc J W van der Laan
Journal:  Mol Med       Date:  2022-06-28       Impact factor: 6.376

5.  NNMT promotes the progression of intrahepatic cholangiocarcinoma by regulating aerobic glycolysis via the EGFR-STAT3 axis.

Authors:  Shounan Lu; Shanjia Ke; Chaoqun Wang; Yanan Xu; Zihao Li; Keda Song; Miaoyu Bai; Menghua Zhou; Hongjun Yu; Bing Yin; Xinglong Li; Zhigang Feng; Yongliang Hua; Shangha Pan; Hongchi Jiang; Linqiang Li; Yaohua Wu; Yong Ma
Journal:  Oncogenesis       Date:  2022-07-18       Impact factor: 6.524

6.  Effects of Afatinib on Development of Non-Small-Cell Lung Cancer by Regulating Activity of Wnt/β-Catenin Signaling Pathway.

Authors:  Yue Wu; Jiajing Zhang; Changping Yun; Chenchen Dong; Ye Tian
Journal:  Comput Math Methods Med       Date:  2022-06-28       Impact factor: 2.809

7.  Bortezomib induces methylation changes in neuroblastoma cells that appear to play a significant role in resistance development to this compound.

Authors:  Karolina Łuczkowska; Katarzyna Ewa Sokolowska; Tomasz K Wojdacz; Bogusław Machaliński; Olga Taryma-Lesniak; Krzysztof Pastuszak; Anna Supernat; Jonas Bybjerg-Grauholm; Lise Lotte Hansen; Edyta Paczkowska
Journal:  Sci Rep       Date:  2021-05-10       Impact factor: 4.379

8.  Microtissue Geometry and Cell-Generated Forces Drive Patterning of Liver Progenitor Cell Differentiation in 3D.

Authors:  Ian C Berg; Erfan Mohagheghian; Krista Habing; Ning Wang; Gregory H Underhill
Journal:  Adv Healthc Mater       Date:  2021-04-23       Impact factor: 11.092

9.  HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer.

Authors:  Caterina Vivaldi; Lorenzo Fornaro; Clara Ugolini; Cristina Niccoli; Gianna Musettini; Irene Pecora; Andrea Cacciato Insilla; Francesca Salani; Giulia Pasquini; Silvia Catanese; Monica Lencioni; Gianluca Masi; Daniela Campani; Gabriella Fontantini; Alfredo Falcone; Enrico Vasile
Journal:  Oncologist       Date:  2020-05-11       Impact factor: 5.837

10.  The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers.

Authors:  Angela Lamarca; Salvatore Galdy; Jorge Barriuso; Sharzad Moghadam; Elizabeth Beckett; Jane Rogan; Alison Backen; Catherine Billington; Mairéad G McNamara; Richard A Hubner; Angela Cramer; Juan W Valle
Journal:  PLoS One       Date:  2018-10-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.